Mayne Pharma | MYX - 资产



金融业
股票价格
AUD
资产
AUD 1.14B
现金及等价物
AUD 110.07M
销售成本
AUD 43.74M
流动资产
AUD 460.59M
流动负债
AUD 313.94M
债务
AUD 38.82M
EBIT
AUD -16.2M
EBITDA
AUD 20.9M
员工
450
EPS每股收益
AUD 0.31
股本和储备
AUD 454.19M
销售毛利
AUD 86.13M
债务利息支出
AUD 1.2M
贷款资金
AUD 2.66M
市值
AUD 264.58M
净收入
AUD -103.68M
营业费用
AUD 103.54M
营业利润
AUD -3.3M
普通股股本
AUD 81.25M
税前利润
AUD -14.7M
销售收入
AUD 86.5M
销售和管理费用
AUD 54.8M
股票
AUD 74.63M
贸易债权人
AUD 30.25M
应收帐款人
AUD 193.22M


资产 更改 日
Ansell USD 3.33B 3.2M 2025-12
Avita Medical AUD 56.39M 1.74M 2025-12
Cochlear AUD 2.79B 31.3M 2025-12
CSL USD 37.9B 1.5B 2025-12
Healius AUD 3.07B 84.2M 2024-12
Integral Diagnostics AUD 744.28M 1.52M 2024-06
Medical Developments International AUD 63.57M 2.83M 2025-12
Nanosonics AUD 279.25M 6.77M 2025-12
Polynovo AUD 123.37M 4.04M 2025-12
Ramsay Health Care AUD 21.7B 777.8M 2025-12
ResMed USD 8.78B 280.91M 2026-03
Sigma Healthcare AUD 8.29B 6.91B 2025-12
Sonic Healthcare AUD 15.38B 550.57M 2024-12
Telix Pharmaceuticals AUD 1.36B 197.86M 2026-06